1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
CellaVision AB (publ)

CellaVision AB (publ)

CLVSF
CellaVision AB (publ)US flagOther OTC
13.49
USD
- -
- -
321.76MMarket Cap
CellaVision AB (publ)
CLVSF
(Other OTC)

Recent

price

13.49

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.52
6.52
7.11
7.54
9.09
10.04
11.11
12.97
15.29
19.36
19.77
23.71
26.8
28.4
30.32
31.82
30.63
Revenue per Share
1.61
0.61
0.27
0.79
1.32
2.21
2.51
2.92
3.72
4.16
3.75
5.25
4.96
5.46
5.9
6.42
5.62
Basic EPS, GAAP
0.47
1.09
0.02
0.65
1.09
3.3
2.57
2.47
2.92
5.17
2.64
6.7
5.76
8.24
8.32
8.41
8.45
Free Cash Flow per Basic Share
- -
0.21
0.4
0.4
0.5
1
1.5
1.5
1.5
1.5
- -
0.75
2
2.25
2.25
2.5
2.5
Dividend per Share
4.2
4.82
4.69
5.08
5.9
7.11
8.12
9.54
11.76
14.42
18.17
22.68
25.64
28.85
32.5
36.42
- -
Book Value per Share
4.76
4.39
4.22
4.45
5.2
6.46
7.19
7.85
9.33
2.04
5.4
7.76
10.16
11.87
13.75
15.04
15.77
Tangible Book Value per Share
24
24
24
24
24
24
24
24
24
24
24
24
24
24
24
24
24
Basic Weighted Avg Shares
132
155
170
180
217
239
265
309
365
462
471
566
639
677
723
759
731
Sales/Revenue/Turnover
10.6
11.45
12.21
14.43
19.74
27.35
27.98
29.39
30.59
27.41
23.39
28.77
24.75
24.66
24.57
26.62
23.74
Operating Margin (%)
- -
6
8
9
13
8
8
8
7
20
32
33
40
40
41
40
- -
Depreciation Expense
38
15
6
19
31
53
60
70
89
99
89
125
118
130
141
153
134
Net Income, GAAP
- -
20.96
65.23
23.32
27.45
19.42
21.08
22.82
20.88
23.25
20.27
20.82
20.28
20.65
20.43
21.2
21.25
Effective Tax Rate (%)
29.13
9.42
3.81
10.53
14.51
22.07
22.56
22.54
24.31
21.48
18.98
22.16
18.51
19.24
19.46
20.17
18.35
Profit Margin (%)
36
53
60
70
98
140
167
188
223
139
194
230
244
246
294
330
348
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
123
87
96
60
29
13
12
10
LT Debt
113
126
125
133
151
184
206
241
290
348
430
543
642
716
816
888
914
Total Equity
- -
10.05
5.12
13.64
20.13
30.97
29.68
31.02
32.85
23.69
16.17
20.7
17.69
17.37
17.41
18.14
15.19
Return on Invested Capital (%)
- -
11.7
5.17
14.36
22.22
33.4
32.49
32.73
34.52
24.99
16.89
20.39
17.28
18.12
18.29
18.13
611.39
Return on Capital (%)
47.32
13.61
5.69
16.26
24.03
34.04
32.92
33.1
34.91
31.76
23.02
25.73
20.54
20.05
19.23
18.62
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
14
14
12
LT Borrowings
13
12
10
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
24
Market Capitalization
4,342
3,710
3,659

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
426
441
472
Cash, Cash Equivalents & STI
159
188
230
Accounts Receivable, Net
130
120
91
Inventories
113
112
122
Total Current Liabilities
129
111
124
Payables & Accruals
- -
- -
- -
ST Debt
14
14
12
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.19%
15.78%
8.81%
Free Cash Flow
20.5%
36.94%
1.06%
Net Income, GAAP
12.04%
12.27%
8.78%
Sales/Revenue/Turnover
12.47%
10.13%
4.94%
Total Cash Common Dividend
- -
- -
11.11%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
170
188
179
187
723
2025
195
191
176
197
759
2026
166
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.26
1.62
1.3
1.72
5.9
2025
1.74
1.58
1.31
1.79
6.42
2026
0.94
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
2.25
- -
- -
2.25
2025
- -
2.5
- -
- -
2.5
2026
- -
- -
- -
- -
- -
Similar Companies
Surmodics, Inc. (SRDX)
S&S Healthcare Holding Ltd. (4198.TWO)
ReWalk Robotics Ltd. (RWLK)
Demant A/S (DEMANT.CO)
Theraclion S.A. (TCLIF)
Allied Healthcare Products, Inc. (AHPIQ)
Business
CellaVision AB (publ) specializes in digital solutions for blood and body fluid analysis within the healthcare sector, serving a global market spanning Sweden, across Europe, the Middle East, Africa, the Americas, and the Asia Pacific region. The company provides advanced diagnostic instruments, including the CellaVision DM1200 and DM9600 systems, which digitally capture cellular images from blood smears and body fluid samples to automate analysis. Additionally, their CellaVision DC-1 analyzer is designed to streamline blood cell differentials, particularly for smaller laboratories. The product portfolio extends to a comprehensive suite of software applications. This includes the CellaVision Peripheral Blood Application, which standardizes and simplifies the morphological assessment of peripheral blood smears, and the CellaVision Advanced RBC Application, enabling detailed red blood cell morphology examinations. For body fluid analysis, the CellaVision Body Fluid Application automates morphological review, while the CellaVision Remote Review Software facilitates off-site slide interpretation, overcoming geographical barriers. Further offerings comprise CellaVision Server Software for integrated workflows across multiple testing locations, CellaVision Dashboard for monitoring analyzer performance and reviewer metrics, and CellaVision Proficiency Software, a cloud-based platform for evaluating and enhancing staff competency in cell morphology. Educational resources are also available through CellaVision CellAtlas, featuring mini-lectures and an extensive cell image library, alongside CellaVision VET, which offers digital microscopy tools tailored for veterinary hematology. CellaVision enhances laboratory efficiency and diagnostic accuracy by developing instruments, reagents, and software, including solutions for smear making and staining. The company primarily targets hospitals and commercial laboratories of various sizes, supporting both human and animal sample analysis. The firm also focuses on innovation, dedicating a significant portion of its revenue to research and development, particularly in areas like artificial intelligence and Fourier Ptychographic Microscopy. Recent developments include strategic partnerships aimed at advancing hematology solutions, new product application launches, and ongoing clinical trials for expanded capabilities such as bone marrow analysis, expected to reach the market by early 2026. Established in 1994, CellaVision AB (publ) maintains its headquarters in Lund, Sweden.

Company News

APIChat

  • seekingalpha.com

    CellaVision AB (publ) (CLVSF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    CellaVision AB (publ) (CLVSF) Q3 2025 Earnings Call Transcript